Investors focused on the Medical space have likely heard of Audentes Therapeutics (BOLD), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Audentes Therapeutics is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BOLD is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for BOLD's full-year earnings has moved 6.80% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the most recent data, BOLD has returned 30.08% so far this year. Meanwhile, the Medical sector has returned an average of 2.81% on a year-to-date basis. This means that Audentes Therapeutics is performing better than its sector in terms of year-to-date returns.Breaking things down more, BOLD is a member of the Medical - Biomedical and Genetics industry, which includes 281 individual companies and currently sits at #109 in the Zacks Industry Rank. This group has gained an average of 1.16% so far this year, so BOLD is performing better in this area.Going forward, investors interested in Medical stocks should continue to pay close attention to BOLD as it looks to continue its solid performance.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Audentes Therapeutics, Inc. (BOLD): Free Stock Analysis Report To read this article on Zacks.com click here.